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Oxidative stress reflects an imbalance between oxidants and antioxidants in favor of the oxidants capable of evoking tissue damage.
Like hydrogen sulfide (H2S) and nitric oxide (NO), carbon monoxide (CO) is an endogenous gaseous mediator recently implicated
in the physiology of the gastrointestinal (GI) tract. CO is produced in mammalian tissues as a byproduct of heme degradation
catalyzed by the heme oxygenase (HO) enzymes. Among the three enzymatic isoforms, heme oxygenase-1 (HO-1) is induced
under conditions of oxidative stress or tissue injury and plays a beneficial role in the mechanism of protection against
inflammation, ischemia/reperfusion (I/R), and many other injuries. According to recently published data, increased endogenous
CO production by inducible HO-1, its delivery by novel pharmacological CO-releasing agents, or even the direct inhalation of
CO has been considered a promising alternative in future experimental and clinical therapies against various GI disorders.
However, the exact mechanisms underlying behind these CO-mediated beneficial actions are not fully explained and
experimental as well as clinical studies on the mechanism of CO-induced protection are awaited. For instance, in a variety of
experimental models related to gastric mucosal damage, HO-1/CO pathway and CO-releasing agents seem to prevent gastric
damage mainly by reduction of lipid peroxidation and/or increased level of enzymatic antioxidants, such as superoxide
dismutase (SOD) or glutathione peroxidase (GPx). Many studies have also revealed that HO-1/CO can serve as a potential
defensive pathway against oxidative stress observed in the liver and pancreas. Moreover, increased CO levels after treatment
with CO donors have been reported to protect the gut against formation of acute GI lesions mainly by the regulation of reactive
oxygen species (ROS) production and the antioxidative activity. In this review, we focused on the role of H2S and NO molecular
sibling, CO/HO pathway, and therapeutic potential of CO-releasing pharmacological tools in the regulation of oxidative stress-
induced damage within the GI tract with a special emphasis on the esophagus, stomach, and intestines and also two solid and
important metabolic abdominal organs, the liver and pancreas.
1. Introductory Notes
1.1. Oxidative Stress. According to Sies et al., oxidative stress
can be defined as an imbalance between oxidants and antiox-
idants in favor of the oxidants, leading to a disruption of
reduction-oxidation (redox) signaling and control and/or
molecular damage [1, 2]. Oxidative stress, in terms of its
intensity, may be divided into eustress (physiological/positive
stress) that plays several beneficial roles in physiological pro-
cesses [1, 2] and excessive oxidative stress (distress/chronic/-
toxic stress) that may lead to the development and
progression of pathological conditions [2–4]. Interestingly,
recent reports indicated that oxidative stress can have a dual
role in cancer development; on the one hand, it can promote
molecular genetic alterations resulting in cancer cell transfor-
mation. On the other hand, it is also a necessary anticancer
response-activating apoptotic pathway leading to selective
cancer cell elimination [5, 6].
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Reactive species, such as reactive oxygen species (ROS),
nitrogen species (RNS), sulfur species (RSS), or carbonyl spe-
cies (RCS), have a notable impact on redox signaling and oxi-
dative stress [2, 4]. ROS, the most extensively studied
component of oxidative stress, include free radicals such as
superoxide radicals (O2
⋅−) or hydroxyl radicals (OH⋅) and
nonradical species such as hydrogen peroxide (H2O2) or sin-
glet molecular oxygen (1O2) [2].
Under physiological conditions, production of ROS is
highly restricted to specific enzymes that include the
NADPH oxidases, xanthine oxidase, uncoupled endothelial
nitric oxide synthase (eNOS), and the mitochondrial electron
transport chain (mtETC) [7]. In order to protect themselves
from ROS, the antioxidant defensive systems based on enzy-
matic or nonenzymatic components are activated and
expressed within the cells. Enzymatic antioxidants, belonging
to the first line of cellular defense system, include superoxide
dismutase (SOD), catalase (CAT), and glutathione peroxi-
dase (GPx). Nonenzymatic, the second line of defense,
include glutathione (GSH) or vitamin E [3, 8]. However, it
should be kept in mind that the abovementioned antioxi-
dants may also contribute to oxidative damage. For instance,
according to Sies et al., H2O2, an uncharged molecule, per-
forms a major function in the course of oxidative stress rather
than free radicals [9]. This is mainly due to its stability and
ability to cross the cellular membranes and deliver a redox
signal to distant targets [9]. Thus, enzymes such as SOD, cat-
alyzing the conversion of O2
⋅− to H2O2, may have a dual
effect: the first is a classical superoxide scavenger and the sec-
ond can be the involvement of this enzyme in the regulation
of ROS signaling [10].
Gastrointestinal (GI) tract is especially vulnerable to ROS
attack due to constant contact with ingested materials and
microbial pathogens. Moreover, ROS as well as RNS, such
as nitric oxide (NO) and peroxynitrite (OONO-), are exces-
sively produced during inflammatory states developed
throughout the digestive system [11]. Oxidative stress has
been implicated in a variety of major GI tract disorders
including peptic ulcers; inflammatory bowel disease (IBD);
and gastric, esophageal, and colorectal cancers [5, 12].
1.2. Carbon Monoxide. Carbon monoxide (CO) is a danger-
ous gas, produced by incomplete combustion of carbon-
containing materials. It is tasteless, odorless, and colorless.
CO binds to the hemoglobin (Hb) forming carboxyhemoglo-
bin (COHb) with about 210 to 250 times greater affinity than
that of oxygen. Such binding reduces the oxygen transporta-
tion ability of Hb leading to cellular hypoxia [13]. However,
CO is also an endogenously generated gaseous mediator,
which is produced during heme degradation via the activity
of heme oxygenase (HO) enzymes. Currently, three main iso-
forms of HOs have been described, but only HO-1 and HO-2
have been defined as biologically active. HO-1 is a stress-
inducible enzyme which represents a defense mechanism
against oxidation and inflammation and is regulated by the
transcription factor AP-1 activated by oxidative stress [14].
In contrast to HO-1, the isoform HO-2 is expressed constitu-
tively [15]. Both, HO enzymes cleave the alpha-methylene
carbon bond of the porphyrin ring of heme with the involve-
ment of NADPH and molecular oxygen to yield equimolar
amounts of biliverdin (BV), iron, and CO [16]. It is widely
recognized that CO binds to a range of intracellular proteins
containing heme prosthetic group, for instance, cytochrome
c oxidase, cytochromes P450, myoglobin, guanylate cyclase,
catalase, or cystathionine β-synthase (CBS) [16, 17].
It has been reported that endogenous CO-producing
enzymes are expressed within the GI tract. Precisely, BV
reductase (BVR) with the ability to convert BV to bilirubin
and HO-2 are present in mucosal epithelial cells and in the
endothelium of intramural vessels of the human gastric fun-
dus [18]. Moreover, these proteins are localized in intramus-
cular interstitial Cajal cells (ICC) and in intrinsic nerve cell
bodies of the submucosal and myenteric plexuses [18]. In
rats, HO-2 was identified in gastrin cells of the pyloric glands
and in parietal cells of the oxyntic glands [19]. Inducible HO-
1 was shown to be expressed in mononuclear cells in the sub-
mucosa with minor staining in the epithelial cells of patients
with ulcerative colitis [20]. HO-1 is expressed in endothelial
cells of the mucous neck region of the gastric mucosa [21].
Moreover, this protein was localized in sinusoidal cells of
the rat’s liver [21]. Interestingly, pharmacological inhibition
of HO by zinc protoporphyrin IX resulted in the attenuation
of vasoactive intestinal polypeptide- (VIP-) induced low
esophageal sphincter relaxation implying that this enzymatic
protein contributes to the regulation of the motor activity of
the upper GI tract [22–24].
In the GI tract, the gaseous molecule CO has been shown
to exert many physiological functions including its contribu-
tion to the mechanism of cell signaling, cytoprotection, regu-
lation of microcirculation, motility, and modulatory effect of
pathological events such as inflammation and carcinogenesis
[25]. Moreover, exogenous and endogenous CO can be
involved in redox signaling and initiate a compensatory
expression of antioxidant enzymes and other adaptations to
oxidative stress (Figure 1.) [15]. To summarize, the pleio-
tropic effect of CO, with an emphasis on redox biology,
may improve clinical usefulness and applicability of CO-
releasing molecules (CO donors) and their implementation
in various therapeutic areas in the near future.
1.3. CO and Other Gaseous Mediators in Regulation of
Oxidative Stress in the Digestive System. Endogenous CO,
similarly to other two gaseous mediators, hydrogen sulfide
(H2S) or nitric oxide (NO), can exert a variety of biologic
and physiologic functions which range from the regulation
of vascular tone, mitochondrial homeostasis and biogenesis,











Figure 1: Schematic crosstalk between carbon monoxide and
antioxidative enzymes. Arrows or blunt ends indicate activation or
inhibition, respectively. Blue lines indicate CO-mediated
processes; red lines indicate oxidative stress-mediated effects.
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programmed cell death to cellular proliferation programs
[26]. However, CO, unlike NO and H2S, is not a free radical
and does not alternate between different oxidative species;
thus, it is considered more biologically stable [25, 27].
Interestingly, according to recently published data, the
gaseous mediators CO, H2S, and NO were shown to play
an important role within the GI tract [28, 29]. A large
number of studies have focused on the contribution of these
gaseous transmitters in the stomach’s defensive response
against gastric mucosal injury with special emphasis to possi-
ble interaction between them. For example, it has been
reported that CO-releasing CORM-2, similarly to H2S
released from NaHS, protected gastric mucosa against
alendronate-induced damage in the gastric mucosa compro-
mised by oxidation evoked by exposure to chronic mild stress
[30]. Both mediators decreased the mRNA expression for
nuclear factor κB (NF-κB) [30]; however, the direct interac-
tion between the enzymatic pathways of endogenous H2S
and CO still remained insufficiently explained. Interestingly,
CO and H2S donors were demonstrated to reduce aspirin-
induced gastric damage and lipid peroxidation observed as
documented by an increase in the malondialdehyde (MDA)
concentration in the gastric mucosa [31]. Similarly, NO was
shown to attenuate nonsteroidal anti-inflammatory drug-
(NSAID-) induced gastric bleeding [32, 33]. Pretreatment
with NaHS and CORM-2 elevated gastric mucosal protein
expression for antioxidative GPx but not for SOD [31]. Both
molecules caused the antioxidative effects to be dependent on
endogenous NO production [31]. Nevertheless, CORM-2-
mediated gastroprotection and acceleration of ulcer healing
was independent of H2S biosynthesis while NaHS was not
effective when endogenous CO production was pharmaco-
logically inhibited [34, 35]. It is worth to mention that CO
and H2S donors were reported to protect the GI tract against
acute oxidative damage induced by ischemia/reperfusion
(I/R) injury [36, 37]. However, the NO/constitutive nitric
oxide synthase (cNOS) pathway was shown to prevent I/R-
induced gastric lesions while the activation of the NO/indu-
cible nitric oxide synthase (iNOS) molecular pathway activity
exacerbated this damage [38]. Interestingly, it was observed
that H2S-releasing naproxen (ATB-346) exerted its GI safety
as compared with the classic form of this drug in the gastric
mucosa compromised by acute experimental stress due to
modulation of gastric mucosal HO expression [39]. Taken
together, all three gaseous mediators and their pharmaco-
logical donors afforded protective activity by the activation
of antioxidative activity within the digestive system. How-
ever, the precise mechanism of possible interaction between
these molecules in the context of oxidative stress modula-
tion and prevention remains to be explained and requires
further studies.
1.4. Carbon Monoxide Delivery Systems. There are various
pharmacological and chemical tools available with the ability
to modulate the concentration of CO in vitro and in vivo.
This could include induction or inhibition of HO activity
by hemin or zinc protoporphyrin IX, respectively [13]. How-
ever, recent approach has been concentrated on the pharma-
cological delivery of exogenous CO in a controllable manner
and directly to the target tissue. It is worth to mention that
the easiest way seems to be a systemic inhalation of a gas
mixture containing CO but this concept is limited due to
difficulties with storage and CO delivery in a controlled
and directed manner [40–42]. Thus, Motterlini et al. pro-
posed a series of transition metal carbonyls, termed CO-
releasing molecules (CORMs) that are able to liberate CO
and therefore to provide the direct biological effects to
organs and tissues [41]. Being the first identified, the acro-
nym CORM-1 (also known as DMDC) was assigned to
dimanganese decacarbonyl (Mn2(CO)10). CORM-2 acro-
nym was assigned to the tricarbonyldichlororuthenium
(II) dimer ((Ru(CO)3Cl2)2) [42]. Both CORM-1 and CORM-
2 are soluble in organic solvents. Moreover, CORM-2 and
next-generation CORMs contain in their structure heavy
metals, such as ruthenium that may potentially restrict their
implementation into clinical pharmacology. In addition, the
release of CO from these molecules requires photoactivation,
as it is in the case of CORM-1 and ligand substitution for
CORM-2 [42]. Therefore, novel water-soluble CO delivery
molecules were described, tricarbonylchloro (glycinato)
ruthenium II (RuCl(glycinato)(CO)3), termed CORM-3;
boron-based compound Na2H3BCO2, named CORM-A1; or
recently developed CORM-401 (Mn(CO)4 [43]) that in con-
trast to CORM-A1 releases up to three equivalents of CO per
mol of the compound [42–44]. Additionally, the new class of
organic CO-releasing prodrugs was developed recently [42,
45–47]. These COprodrugs do not contain heavymetals, have
a long half-life, and are able to release CO in a controllable
manner. Importantly, few of them are activated to release CO
only in contact with specific tissue enzymes, such as esterase
and low pH on a click and release basis [42, 45–47]. Interest-
ingly, some of these new compounds were developed as CO
releasers in the presence of ROS [43].
2. CO and Oxidation within the
Digestive System
2.1. Esophageal Mucosa. Esophageal mucosa is continuously
exposed to external noxious agents and therefore is predis-
posed to epithelial damage [48]. Gastroesophageal reflux dis-
ease (GERD) resulting from the influx of the acidic stomach
content into the esophagus is considered nowadays the global
disease of the upper GI tract leading to the development of
esophageal inflammation and oxidation [49]. It has been
reported in rat models of reflux esophagitis that pretreatment
with antioxidative isorhamnetin decreased esophageal lesion
score reducing MDA levels, possibly due to the upregulation
of the esophageal HO-1 expression [50]. Additionally, in cul-
tured esophageal epithelial cells (EEC), it has been observed
that euptailin prevented indomethacin-induced cytotoxicity
and upregulated HO-1 expression due to nuclear transloca-
tion of transcription factor nuclear factor erythroid 2-
related factor 2 (Nrf2) and the activation of extracellular
signal-regulated kinases (ERKs) and phosphatidylinositol-3-
kinase (PI3K)/Akt signaling [24, 51]. However, possible
involvement of HO and CO and their possible interaction
in the regulation of oxidative stress in the esophageal mucosa
requires further investigations.
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2.2. Gastric Mucosa. Stomach and gastric mucosa are impor-
tant components of the GI tract, responsible for digestion, GI
motility, and early microbial defense [52]. Oxidative stress,
induced in response to exogenous gastric mucosal irritants,
drugs, and pathogens derived from food intake, is one of
the major contributors to the pathogenesis of gastric disor-
ders such as gastritis, gastric ulcers, and gastric cancer and
also drug-induced toxicity [53].
Importantly, the HO-1/CO pathway and CO donors
has been considered one of protective factors involved in
the protection of the gastric mucosa against numerous
injuries mediated by oxidative stress. The most important
antioxidative effects of CO donors in various in vitro and
in vivo experimental models of gastric mucosa injuries were
summarized in Table 1 with special attention paid to the
dosages used and the form of pharmacological source of
this gaseous molecule.
2.2.1. HCl- and Ethanol-Induced Mucosal Damage. In an ani-
mal model of acute gastric mucosal lesions induced by the
application of HCl, Ueda et al. have demonstrated that HO-
1 mRNA expression level was upregulated and pretreatment
with HO-1 inhibitor exacerbated the severity of these lesions
[54]. Accordingly, Gomes et al. have evaluated the role of
HO-1/BV/CO pathway in gastric mucosal defense against
ethanol-induced gastric damage in mice [55]. They revealed
the gastroprotective effects of hemin (HO-1 inducer), BV,
and CO donor dimanganese decacarbonyl (DMDC) against
the damage induced by this necrotizing agent by a mecha-
nism involving a decrease in free radical production. More-
over, in mice treated with this CO donor, the reduced
formation of MDA considered a marker of lipid peroxidation
and increased GSH concentrations have been observed in the
gastric mucosa with ethanol-induced gastropathy [55].
2.2.2. Drug-Induced Mucosal Damage. Costa et al. have eval-
uated the gastroprotective effect of HO-1/CO pathway
against alendronate-induced gastric damage in rats [56]. In
their study, pretreatment with hemin or DMDC reversed
the fall in gastric GSH levels and the rise in MDA level ele-
vated after alendronate administration [56]. Thus, they con-
cluded that COmay restore the mechanisms of redox balance
and protects the gastric mucosa by the reduction in lipid per-
oxidation in this experimental model [56]. The question
arises whether CO may play an important role in the protec-
tion of the gastric mucosa injured by the combination of
ulcerogenic factors. Indeed, it has been demonstrated that
CO released from CORM-2 is able to protect against
alendronate-induced gastric lesions even when the gastric
mucosa has previously been exposed to chronic mild stress
[30]. In this chronic animal model, CORM-2 did not affect
the mRNA expression of antioxidative enzymes GPx-1 and
SOD-2 but decreased the expression of mRNA for oxidative
marker NF-κB, upregulated by treatment with alendronate
Table 1: Antioxidative effects of CO donors in various in vitro and in vivo experimental models of gastric mucosal injury or gastric cancer.
Experimental model (publication) CO donor Dose Form of application
Ethanol-induced gastric
damage mouse model [55]
DMDC 12.5μmol/kg Intraperitoneal injection
↓ Lipid peroxidation, ↑ GSH
Alendronate-induced gastric
damage rat model [56]
DMDC 81μmol/kg Intraperitoneal injection
↓ Lipid peroxidation, ↑ GSH
Alendronate-induced
gastric damage + mild
stress rat model [30]
CORM-2 5mg/kg Intragastric injection





CORM-2 1mg/kg Intragastric injection
↓ Lipid peroxidation, restored activity of gastric mucosal SOD and GSH, and attenuated GPx-1
and SOD-2 gene expression
Acute aspirin-induced gastric
damage rat model [31]
CORM-2 5mg/kg Intragastric injection
↓ Lipid peroxidation, ↓ IL-1β gene expression, restored activity of GPx-1
Human gastric
adenocarcinoma
(AGS) cell line [60]
CORM-2 10, 25, 50μM
Incubation with
medium containing CO
↓ IL-1β induced IL-8 gene and protein expression, ↓ IL-8 promoter activity,
↓ IL-1β induced ROS production
4 Oxidative Medicine and Cellular Longevity
in the gastric mucosa compromised by stress [30]. In another
study [57], CORM-2 restored the activity of gastric muco-
sal antioxidant enzymes SOD and GSH, both decreased
under stress conditions, and attenuated the expression of
SOD-2 and GPx-1 mRNA, both markedly increased in the
stressed gastric mucosa [57]. Additionally, pretreatment with
CORM-2 exhibited beneficial effects in counteracting acute
aspirin-induced gastric damage. CORM-2 inhibited gastric
mucosal lipid peroxidation and restored antioxidative
GPx-1 protein expression impaired by aspirin treatment,
thus supporting an important role of CO in the protection
of the gastric mucosa against oxidative injury [31]. Interest-
ingly, in the same experimental model, CORM-2 abrogated
the expression of proinflammatory cytokine IL-1β [31]. This
pleiotropic cytokine IL-1β is associated with enhanced
metastasis and poor prognosis of gastric cancer and was
reported to stimulate the expression of IL-8, another inflam-
matory cytokine, through mitogen-activated protein (MAP)
kinase and ROS signaling [31, 58]. Interestingly, hexacarbo-
nyldicobalt derivative of aspirin considered a CO-releasing
aspirin has been reported to decrease the ROS/RNS generation
in malignant pleural mesothelioma (MPM) cell lines [59].
Taking into account the antioxidative activity of CO donors
against NSAID-induced GI damage, we conclude that the
development of novel safer CO-releasing derivatives of these
drugs should be considered a new therapeutic option in
limiting serious parent NSAID-induced complications which
deserve attention of basic scientists and clinical practitioners.
2.2.3. Gastric Cancer In Vitro Models. Besides in vivo animal
models of ulcerogenesis, in vitro studies have been carried
out to investigate the role of CO in gastric cancer. Lian
et al. [60] have used CORM-2 (10, 25, and 50μM) to investi-
gate the effect of CO on IL-1β-induced expression of IL-8
in human gastric cancer AGS cells. They observed that
CORM-2 suppressed IL-1β-induced IL-8 expression and
effectively inhibited IL-1β-induced ROS production deter-
mined by the H2O2-sensitive fluorophore DCFDA [60].
These observations support the notion that the antioxidant
properties of CO and its ability to inhibit expression of
proinflammatory cytokines such as IL-1β, can contribute,
at least in part, to the gastroprotective effect of these gas-
eous molecules. However, it seems likely that the detailed
mechanism by which CO attenuates ROS formation may
strongly depend on the chosen experimental model and
still remains to be elucidated.
2.3. Intestinal Mucosa. The intestine is responsible for diges-
tion and absorption of nutrients, electrolytes, water, bile salts,
and drugs. It also possesses immunological, endocrine, and
motility response regulating functions [61]. The increased
availability of CO levels in the intestinal compartment bene-
ficially affects a course of various disorders, for example IBD,
sepsis, postoperative ileus (POI), and outcomes following
intestinal transplant in experimental animal models and pre-
liminary studies in humans. Most of these diseases are
directly or indirectly associated with inflammation and/or
increased oxidative stress [62]. The most important antioxi-
dative effects of CO donors in various in vitro and in vivo
experimental models of intestinal mucosa injuries were sum-
marized in Table 2.
2.3.1. IBD. CO/HO-1 pathway and exogenous CO with its
immunomodulatory properties and protective activities
against oxidative stress reached increased importance due
to its beneficial effects observed in the course of chronic
intestinal inflammatory diseases, including the most com-
mon forms of IBD like ulcerative colitis (UC) and Crohn’s
disease (CD) [62–65]. For instance, the therapeutic potential
of CO was evaluated by Takagi et al. in 2,4,6-trinitrobenzine
sulfonic acid- (TNBS-) induced colitis in mice. They
observed that increased colonic damage after TNBS adminis-
tration was inhibited by the pretreatment with inhaled CO.
Furthermore, CO significantly attenuated the production of
thiobarbituric acid- (TBA-) reactive substances being inter-
preted in this study as an index of lipid peroxidation [66].
Additionally, Yin et al. examined the role of CORM-2 in a
murine model of inflammatory colitis induced by the
treatment with dextran sodium sulfate (DSS) [67]. Interest-
ingly, to overcome drawbacks resulting from the poor aque-
ous solubility of CORM-2 and a very short CO-releasing
half-life, a micelles consisting of water-soluble styrene-
maleic acid copolymer (SMA) that encapsulated CORM-2
(SMA/CORM-2) were designed. SMA/CORM-2 polymers
have shown significant therapeutic and tissue-protective
effects, probably through CO released from the micelles
evoking antioxidative and anti-inflammatory effects [67].
2.3.2. Systemic Inflammation. Wang et al. have shown that
exogenous CO can attenuate inflammatory responses in the
small intestine of septic mice induced by cecal ligation and
puncture [68]. Administration of CORM-2 significantly
attenuated the production of proinflammatory cytokines
(IL-1β and TNF-α) and suppressed lipid peroxidation in
the small intestine of septic mice, considerably decreasing
the formation of oxidants, and thus reducing the tissue oxi-
dative injury. On the other hand, Liu et al. [69] employed
CORM-2 to determine whether they can afford suppression
of inflammatory cytokine production and oxidative stress in
the small intestine of thermally injured mice. The application
of CORM-2 on thermally injured mice decreased the produc-
tion of IL-1β, TNF-α, and IL-8 and led to the significant
downregulation of intestinal MDA tissue levels [69]. In addi-
tion, they also observed that GSH, a key antioxidant, declined
significantly as compared to the control group, while treat-
ment with CORM-2 reversed this effect [69]. Since the
administration of CORM-2 prevents intestinal GSH deple-
tion, it appears that the protective effect of CO donor
involves the activation of an antioxidant defense system in
protecting the intestinal tissue against oxidative stress [69].
Taken together, these studies seem to indicate that CORM-
2 effectively prevents lipid peroxidation in the small intestine
after experimental injury by decreasing the production of
oxidants, which in consequence accounts for reduction of
tissue oxidative injury.
2.3.3. I/R Injury. The potent clinical CO-inducing protec-
tive effects have also been well documented in controlling
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intestinal I/R injury associated with transplantation. The
GI organ damage caused by I/R is a significant problem
in a variety of clinical settings usually associated with a
high morbidity and mortality. Nakao et al. examined the
efficacy of inhaled CO during intestinal cold I/R injury
associated with small intestinal transplantation in rats. They
observed that perioperative CO inhalation at a low concen-
tration (250 ppm) resulted in the downregulation of several
proinflammatory mediators and significantly increased anti-
oxidant response in the intestinal graft, clearly indicating that
in the CO-inhaled group less reactive oxygen metabolites
were produced [70]. Similarly, Scott et al. suggested that a
low dose of inhaled CO (250 ppm) may exhibit potent anti-
inflammatory properties by inhibiting the production of pro-
inflammatory cytokines [71]. They have also demonstrated a
significant increase in ileum lipid peroxidation/oxidative
stress following hindlimb I/R in male mice; however, as indi-
cated by elevated MDA and remote intestinal mucosal injury,
these events could not be efficiently prevented by a low dose
of inhaled CO [71].
2.3.4. POI. Transient impairment of gastrointestinal motility,
termed POI, is a major determinant of recovery after abdom-
inal surgery which leads to increasedmorbidity and prolonged
patient hospitalization [72]. Backer et al. demonstrated that
pretreatment with CORM-3 ameliorated the POI in surgically
operated small intestine in mice. CORM-3 markedly reduced
oxidative stress in both the intestinal mucosa and muscularis
propria. Interestingly, pharmacological HO inhibition par-
tially reversed the protective effects of CORM-3 on inflamma-
tion/oxidative stress in the muscularis propria and completely
abrogated CORM-3-mediated inhibition of the early “oxida-
tive burst” in the intestinal mucosa of POI. It has been
suggested that this phenomenon might be related to the dys-
function of epithelial barrier and/or the different sources and
amounts of ROS generation in the different layers of the intes-
tine, for example, xanthine oxidase in epithelial cells of the
mucosa versus NADPH oxidase in residential/infiltrated mac-
rophages of the muscular layer [73]. To address these findings
in vitro, studies by Babu et al. have proved the inhibitory influ-
ence of CO on ROS production in intestinal epithelial cells
known to form a semipermeable barrier in the GI tract [74].
During inflammation, this barrier is at risk of damaging the
effects of ROS, cytokines and microbial factors, and cyto-
toxins. In a mouse intestinal epithelial cell line MODE-Κ,
TNF-α/cycloheximide (CHX) was used to induce oxidative
Table 2: Antioxidative effects of CO donors in various in vitro and in vivo experimental models of intestinal mucosa injury.
Experimental model (publication) CO donor Dose Form of application
TNBS-induced colitis
in mice [70]
CO gas 200 ppm Inhalation
↓ Lipid peroxidation
Cecal ligation and puncture-
induced sepsis mouse
model [68]
CORM-2 8mg/kg Intravenous injection




CORM-2 8mg/kg Intravenous injection
↓Lipid peroxidation, ↓ IL-1β production, ↓ IL-8 production, and restored activity of GSH
Cold I/R injury associated
with small intestinal
transplantation in rats [70]





CO gas 250 ppm Inhalation
No protection against intestinal lipid peroxidation
Surgically induced postoperative
ileus mouse model [73]
CORM-3 40mg/kg Intraperitoneal injection
↓ Lipid peroxidation
TNF-α/cycloheximide-induced
oxidative stress in the mouse small




↓ Intracellular ROS level, ↑ GSH
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stress as manifested by the increased ROS production and the
decreased cellular levels of GSH [74]. These effects were par-
tially prevented by treatment with CORM-A1 and correlated
with diminished apoptosis and cell death, suggesting that
modulation of ROS/oxidative stress might be considered a pri-
mary mode of action responsible for the antiapoptotic and
cytoprotective effects of CO [74, 75]. Moreover, CORM-A1
acted solely on NADPH oxidase-derived ROS without major
influence on the mtETC [76]. Nevertheless, the chemical char-
acteristics of different CORMs have a nonnegligible effect on
cellular regulation of ROS sources. As an example, Babu
et al. revealed that the cytoprotective effect of water-soluble
CORM-401 mitigates NADPH oxidase-derived ROS, whereas
lipid-soluble CORM-2 interferes with both NADPH oxidase-
and mitochondria-derived ROS to protect MODE-K cells
from TNF-α/CHX-induced cell death [44, 76].
2.3.5. Colon Cancer In Vitro Models. It is widely known that
ROS induces DNA damages and different genetic disorders
that are critical causes of cancers including colorectal cancer
[77]. Dijkstra et al. have observed that in the human colon
carcinoma DLD-1 cell line, HO-1 is strongly activated by
various oxidative stress-inducing factors, including thiol-
modifying agent diethylmaleate (DEM) and the lipid per-
oxidation end product: 4-hydroxy-nonenal (4-HNE) [14].
Interestingly, they have demonstrated a switch from a
NF-κB-regulated to an activator protein 1- (AP-1-) regu-
lated stress response, which may be controlled by HO-1-
derived CO [14].
2.4. Liver. The liver plays a crucial role in all metabolic pro-
cesses and detoxifies endogenous compounds and xenobiotics,
as a part of the digestive system. Therefore, this organ remains
at the high risk of oxidative injury caused by the production of
ROS. Oxidative stress has been considered a key factor causing
liver damage induced by a variety of chemical and nonchem-
ical agents, including alcohol, drugs, hepatic viral infections,
and nutritional components, which in turn causes progression
of hepatic injury, liver fibrosis, cirrhosis, and in some cases
hepatocellular carcinoma [78–81]. These highly reactive spe-
cies can be responsible for hepatic I/R injury occurring during
surgical procedures such as liver resection and liver transplan-
tation [82, 83]. Themost important antioxidative effects of CO
donors in various in vivo and in vitro experimental models of
liver injury were summarized in Table 3.
2.4.1. I/R Injury. Recently, the HO-1/CO system has been
investigated as a potential mechanism for protection against
oxidative stress and hepatic injury in numerous experimental
models [84]. Brugger et al. provided evidence that CO inha-
lation (250 ppm) or administration of methylene chloride
(MC) can reduce hepatic lipid peroxidation, reestablish total
hepatic glutathione and glutathione disulfide (GSH/GSSG)
ratio, and reduce hepatocellular injury in a murine model
of bilateral hindlimb I/R [85]. The inhalation of CO during
the reperfusion period and the oral gavage of MC caused a
significant increase in COHb content. Moreover, these
authors have attributed the observed reduction in hepatic
ROS formation following CO administration to the inhi-
bition of NADPH oxidase caused by this gaseous mole-
cule [85].
Beneficial effects of CO were also observed by Lee and
colleagues [86] in liver grafts initiated by cold preservation
and augmented by reperfusion. They have shown using an
in vitro model that exposure to 20% CO-containing medium
for 6 h inhibited ROS generation in Kupffer cells (KC) under
hypothermic condition with an upregulation of HSP70
protein [86]. Moreover, pretreatment with inhaled CO
(250 ppm, for 24h before liver graft retrieval) upregulated
hepatic HSP70 protein expression and caused significant
inhibition of cold I/R injury after liver transplantation
in vivo [86]. It was demonstrated that CO bound to red blood
cells (CO-RBC) exhibited the potential to protect hepatic
cytochrome P450 protein, maintaining its ability to exert
resuscitative effect in a rat model of hemorrhagic shock. This
beneficial effect was attributed to the inactivation of KC
resulting in the suppression of ROS production [87]. On
the other hand, Kato have shown that exogenous supple-
mentation with a low dose of bilirubin, an antioxidant
bile pigment, rather than CO could be a crucial factor
that significantly reduces oxidative stress and ameliorates
I/R-induced hepatobiliary dysfunction in rats [88].
The signaling pathway by which CO can protect liver tis-
sues against I/R-injury was studied by Kim et al. [89]. It has
been reported that inhaled CO (250 ppm) attenuated liver
damage via ROS-dependent Akt signaling and by the inhibi-
tion of glycogen synthase kinase 3β (GSK-3β) through Ser9
phosphorylation in the murine model of hepatic warm I/R-
induced injury [89]. Moreover, CO ameliorated hepatic I/R
injury by the regulation of miR-34a/Sirtin1 pathway known
to modulate inflammation and apoptosis in response to
oxidative stress [90]. These data strongly support the con-
clusion that increased bioavailability of CO by treatment
with CO donors could be the promising preventive strat-
egy against I/R injury after liver transplantation and may
provide novel clinical opportunity in the management of
liver disorders due to CO exerting antioxidative and anti-
inflammatory properties.
2.4.2. Alcoholic and Nonalcoholic Liver Damage. Besides
important protective role against I/R injury, CO also con-
ferred substantial prevention against alcoholic liver damage
[91]. In adult male Balb/c mice treated with ethanol or incu-
bated with ethanol primary rat hepatocytes, CO derived from
HO-1 or released from CORM-2 exerted a substantial anti-
oxidant action against oxidative damage in these experimen-
tal models of hepatic injury. This CO-induced protection was
mainly manifested by suppressed lipid peroxidation, normal-
ized GSH concentration, and SOD activity [91]. Further-
more, Upadhyay et al. investigated the therapeutic potential
of CORM-A1 in acetaminophen- (APAP-) induced liver
injury in mice [79]. They showed elevated levels of serum
transaminases, depleted hepatic GSH, and hepatocyte necro-
sis after APAP treatment [79]. On the contrary, in mice
injected with CORM-A1 after APAP administration, the
reduction in serum transaminases, preservation of hepatic
GSH, and attenuation of hepatocyte necrosis have been
observed. Interestingly, mice that received a lethal dose of
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Table 3: Antioxidative effects of CO donors in various in vitro and in vivo experimental models of liver injury.
Experimental model (publication) CO donor Dose Form of application
Hindlimb I/R-induced systemic
inflammation mouse model [85]
CO gas or
MC
250 ppm or 5.8 μmol/kg Inhalation or orally
↓ Lipid peroxidation, ↓ inhibition of NADPH oxidase, and restored GSH/GSSG ratio
Liver transplantation- (LTx-)
induced I/R injury rat model/Kupffer cells isolated
from the liver [86]
CO gas 20% CO-saturated culture medium
Incubation with medium
containing CO
↓ ROS generation, ↑ HSP 70 protein expression
Hemorrhagic shock and
resuscitation rat model/Kupffer
cells isolated from the liver [87]
CO gas





Hepatic warm I/R injury
mouse model [89]
CO gas 250 ppm Inhalation
↑ ROS-dependent PI3 K/Akt activation, ↓ inhibition of GSK3β through Ser9 phosphorylation
Ethanol-induced liver
damage mouse model or
primary rat hepatocytes [91]
CORM-2 8mg/kg or 20μmol/l
Tail vein injection or
incubation with medium
containing CO
↓ Lipid peroxidation, restored GSH level, and restored SOD level
APAP-induced liver




↑ Nrf2 gene upregulation, ↑ ARE gene upregulation, and restored GSH level
HFHF diet-induced hepatic




↑ Nrf2 activation, ↑ ARE gene upregulation, and ↑ ATP production
GalN/LPS-induced acute
liver mouse model [94]
CO gas
First at a dose of 15ml/kg,
and then 6 h later, 8ml/kg
Intraperitoneal injection
↓ Lipid peroxidation, restored GSH level, and restored SOD level
Primary rat or mouse
hepatocytes and Hep3B
cells [96]
CO gas 250 ppm
Incubation with medium
containing CO
↓ Apoptosis, ↓ endogenous antioxidant ascorbic acid, ↓ antioxidant power, ↑ ROS generation, ↑ Akt phosphorylation, and
↓ IκB degradation (= ↑ NF-κB activation)
HepG2 cells [95] CORM-2 80μM for 6 h CO-saturated stock solutions
↑ Nrf2 activation, ↑ HO-1 expression
Tert-butyl hydroperoxide-






↓ ROS generation, ↑ Nrf2 activation
Rat liver mitochondria [98] CO gas 50 ppm for 1, 2, or 7 days Inhalation
↓ GSH/GSSG ratio, ↑ activation of MMP, and ↑ mitochondrial SOD-2




↓ Inhibition of MPP, ↑ mitochondrial ROS generation






↑ Nrf2 activation, ↑ ARE gene upregulation ↓ mitochondrial ROS generation, and ↑ activation of mitochondrial membrane potential
8 Oxidative Medicine and Cellular Longevity
APAP died but those cotreated with CORM-A1 showed a
50% survival [79]. Additionally, CORM-A1 prevented
hepatic steatosis in high-fat high-fructose (HFHF) diet fed
mice, used as a model of nonalcoholic steatohepatitis
(NASH) [92]. The beneficial effects of CORM-A1 in HFHF
fed mice were associated with improved lipid homeostasis,
Nrf2 activation, upregulation of antioxidant-responsive
(ARE) genes, and increased ATP production [92].
The effects of HO-1 and its enzymatic activity products
CO, BV, and iron/ferritin were also assessed in a mouse
model of inflammatory liver damage induced by bacterial
wall cytotoxin lipopolysaccharide (LPS) and hepatocyte-
specific transcription inhibitor D-galactosamine (GalN). It
has been shown that oral administration of the MC or BV
was effective in the protection of hepatic damage in mice,
prolonged their survival, and reduced the expression of proin-
flammatory cytokines (TNF-α, IFN-γ) [93]. Moreover, when
GalN/LPS were administered to induce acute liver damage,
the intraperitoneal injection of exogenous CO gas improved
the survival rate of mice and attenuated hepatocellular dam-
age. Exogenous CO administration markedly reduced MDA
concentrations and restored SOD and GSH levels, thus inhi-
biting lipid peroxidation, whichmight considerably contribute
to the mechanism of CO-mediated hepatoprotection [94].
2.4.3. Hepatocyte In Vitro Models. The important role of CO
in the maintenance of hepatic function in both physiological
and pathophysiological conditions was also demonstrated in
multiple in vitro studies. For instance, Lee et al. have
suggested that CO induces Nrf2 activation via MAP kinase
signaling pathways, thereby prompting an increase in HO-1
expression in HepG2 cells [95]. Similarly, Upadhyay et al.
have revealed that CORM-A1 (10-100μM) facilitated
nuclear translocation of Nrf2, reduced oxidative stress, u-
regulated ARE genes, and prevented GSH depletion promot-
ing cell viability in HepG2 cells treated with tert-butyl hydro-
peroxide (t-BHP), known to cause oxidative stress-mediated
hepatocyte injury [79]. Moreover, Kim et al. [96] have
determined whether the effects of CO are dependent onmod-
ulation of ROS signaling in primary rat- or mouse-derived
hepatocytes and Hep3B cells. They found that CO treatment
(250 ppm) triggered a low level of ROS production in hepato-
cytes in vitro, considered an adaptive response leading to an
increase in cell viability, in combination with Akt phosphor-
ylation and IκB degradation (required for NF-κB activation)
[96]. This finding generated in cultured hepatocytes indicates
the existence of another survival pathway, possibly parallel to
Nrf2 activation [97]. Moreover, exogenous CO failed to
increase ROS production in respiration-deficient Hep3B
cells, suggesting that the mitochondria are the source of
CO-induced ROS generation in this model [96].
2.4.4. Liver Mitochondria. Recently, the possible contribution
of mitochondria as the molecular targets of CO has been
suggested [92, 96, 98]. These key organelles for cell energy
supply play a crucial role in the initiation and progression
of many diseases following oxidative stress-induced damage
[98]. Piantadosi et al. revealed that exposure to gaseous CO
(50ppm) for 1, 3, or 7 days induced hypoxia-sensitive protein
expression for hypoxia-inducible factor 1α (HIF-1α), HO-1,
and SOD-2 in rat liver mitochondria [98]. CO was shown
to induce a profound early mitochondrial oxidative stress
manifested by a decrease in GSH/GSSG ratio and the activa-
tion of the mitochondrial pore transition (MPT) [98]. On the
other hand, Queiroga et al. have demonstrated that low
concentrations of CO (10μM) may inhibit mitochondrial
membrane permeabilization (MMP) in isolated mouse liver
mitochondria in vitro, possibly by preventing mitochondrial
swelling, mitochondrial depolarization, and the opening of a
nonspecific pore through inner membrane [99]. In addition,
CO increased mitochondrial ROS generation that is essential
for signaling of MMP inhibition, although not enough to
induce the damage [99]. Moreover, CORM-A1 significantly
ameliorated mitochondrial function in palmitic acid- (PA-)
treated HepG2 cells via Nrf2 translocation and activation of
cytoprotective gene expression. Furthermore, in PA-treated
cells, CORM-A1 improved mitochondrial oxidative stress,
mitochondrial membrane potential, and rescued mitochon-
drial biogenesis [92].
The abovementioned findings appear to indicate that CO
may have a dual role in oxidative stress and its pro- or anti-
oxidant effects depend on the dosage, route of administra-
tion, the exposure duration, and cell type.
2.5. Pancreas. The pancreas is an important organ for
proper nutrient metabolism that consists of exocrine cells
producing digestive enzymes and endocrine cells responsi-
ble for generation of pancreatic hormones. Malfunction of
the exocrine part can lead to the development of pancreati-
tis and even pancreatic cancer [100, 101]. The most impor-
tant antioxidative effects of CO donors in various in vivo
and in vitro experimental models of pancreatic injury were
summarized in Table 4.
2.5.1. Acute Pancreatitis. Sato et al. have analyzed protein
expression of the heme oxygenase in a rat model of acute
pancreatitis showing that the expression of HO-1 in the pan-
creas in vivo was enhanced. Oxidative stress also elevated
HO-1 expression level in murine islet (LTC3) and rat acinar
(AR42J) pancreatic cells. These findings indicate that HO-1
may act as a potential inflammatory biomarker and a crucial
defense mechanism against oxidative stress in acute pancrea-
titis [102]. It is noteworthy that ROS are possible regulators
of pancreatic injury development. They may activate NF-κB
that regulates gene expression of numerous inflammatory
markers [40, 101]. Chen et al. have demonstrated that
CORM-2-releasing CO exerts beneficial effects on severe
acute pancreatitis in rats. Of note, CORM-2 not only reduced
the serum levels of proinflammatory TNF-α and IL-1β but
also suppressed pancreatic tissue mRNA expression of
TNF-α and IL-1β, whereas anti-inflammatory cytokine IL-
10 was considerably increased. Interestingly, CORM-2 was
also found to suppress NF-κB binding activity which might
testify for the protective, anti-inflammatory, and antioxida-
tive effects of CO in this experimental model [103]. Similarly,
Nuhn et al. have demonstrated that treatment with HO-1
metabolites has a beneficial influence on severity and sur-
vival of acute necrotizing pancreatitis in rats induced by
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retrograde intraductal injection of sodium taurocholate
[104]. Biliverdin hydrochloride (BV-HCl), the CO donor
MC, or iron-chelating desferrioxamine (DFO) was used in
this model [104]. All HO-1 metabolites showed protective
effects on the severity of pancreatitis accompanied by the
diminished pancreatic NF-κB activity [104]. In turn, Nagao
et al. have examined the therapeutic efficacy of CO-bound
Hb vesicle (CO-HbV), a CO carrier, against severe acute
pancreatitis in mice that were fed with a choline-deficient
ethionine-supplemented diet. A CO-HbV treatment signifi-
cantly reduced mice mortality with experimental acute
pancreatitis by inhibiting the systemic release of proinflam-
matory cytokines, neutrophil infiltration, and locally oxida-
tive injuries to the pancreatic tissue [105]. Therefore, the
administration of HO-1 products, including CO, seems to
decrease oxidative stress and attenuate the inflammatory
changes in acute pancreatitis.
2.5.2. Autoimmune Diseases. Interestingly, CO was also iden-
tified as a potential therapeutic molecule for the treatment of
diseases related to pancreas autoimmune diseases, such as
type 1 diabetes. Recently, Nicolic et al. have shown that
CORM-A1 suppressed the incidence and the severity of
immunoinflammatory and autoimmune diabetes in experi-
mental mouse models of type 1 diabetes [106]. Moreover, Li
et al. revealed that the upregulation of HO-1 decreased super-
oxide (O2
⋅ −) generation and increased CO release and biliru-
bin formation in the pancreas of nonobese diabetic mice
[107]. Taken together, these results indicate that enhanced
HO-1 activity associated with increased production of CO
can significantly counteract the diabetic complications [107].
3. Summary
As presented in this review, the gaseous molecule CO plays
an essential physiological role exhibiting beneficial pleiotro-
pic effects in the maintenance of GI tract integrity and the
mechanism of GI mucosal defense (Figure 2). Bioavailability
of CO released from its donors seems to depend onmany fac-
tors, such as dosage of this CO donor, the exposure time, and
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Figure 2: Pleiotropic effects of HO-1/CO pathway against oxidative stress in the digestive system.
Table 4: Antioxidative effects of CO donors in various in vitro and in vivo experimental models of pancreatic injury.
Experimental model (publication) CO donor Dose Form of application
Retrograde infusion of sodium
taurocholate-induced severe acute
pancreatitis rat model [103]
CORM-2 8mg/kg Intravenous injection
↓ NF-κB activity
Retrograde injection of sodium
taurocholate-induced acute necrotizing





pancreatitis mouse model [105]
CO-HbV 1,000mg Hb/kg Via tail vein
↓ Oxidative stress
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sources may give rise to distinct and complex responses in
different parts of the digestive system.
Nevertheless, according to an evidence-based medicine,
the major mechanism of the beneficial action of this gaseous
molecule depends upon cell oxidative metabolism, modula-
tion of ROS generation, and antioxidative activity as reflected
by the expression and activity of antioxidant enzymes (SOD,
GSH) and molecular anti-inflammatory pathways such as
NF-κB or Nrf-2 in the digestive system.
4. Future Perspectives
Due to its antioxidative and anti-inflammatory properties,
CO released from its pharmacological donors or produced
endogenously due to HO-1 activity seems to open new treat-
ment modalities of GI tract disorders by exerting a strong
protective potential which warrants its possible implementa-
tion in digestive system pharmacology. Detailed mechanism
of CO-mediated gastroprotection against gastric mucosal
I/R injury and possible DNA oxidation with special emphasis
on the modulation of mitochondrial activity by this gas still
remains unexplained. Moreover, novel ROS-sensitive CO
prodrugs are promising tools for further investigation,
perhaps in the treatment and prevention of various digestive
system pathologies such as colitis, gastric mucosal injuries,
postsurgical complications, and esophagitis [43]. Therefore,
despite scientific evidence of its efficacy in the protection of
mucosal components of digestive system, the detailed molec-
ular mechanisms by which endogenous CO or CO-releasing
donors exert antioxidative, gastroprotective, and/or thera-
peutic effects in the digestive system still require further
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